Hypertension and nephrology

[Lupus nephritis, 2022]

CZIROK Szabina1, DOLGOS Szilveszter1

FEBRUARY 26, 2022

Hypertension and nephrology - 2022;26(01)

DOI: https://doi.org/10.33668/hn.26.004

[The lupus nephritis (LN) is one of the most frequent manifestation of SLE which causes higher morbiditiy and mortalitiy of the patients if it appears. Although the use of glucocorticoides, cyclophosphamide and mycofenolat mofetil and the protection of the kidney with conservative therapy has significantly improved the outcome of the disease, but the long-term renal outcome and risk of death from LN have not changes over the last 20 years. Furthermore, the side effect of our medications used as part of the standard immunomodulatory therapy are not negligible. The better understanding of the pathomechanism of different medical conditions (hypertension, diabetes mellitus etc.) has helped to combine medications with different therapeutic targets which result more effective and favorable side-effect profile therapy. Therefore, it is not suprising that, in parallel with improvement of the immunology, with better knowlege about the patomechanism of SLE can lead to the new combined, targeted treatments which have broadened the therapeutic options. In addition to the immunmodulatory therapy, a drug with new mechanism of action has become available to slow the progression of chronic kidney diseases. The purpose of this summary is to briefly summarize the current knowledge available and assist clinicians in the daily practice of patients with LN to give suggestion for more effective and personalized therapeutic options.]

AFFILIATIONS

  1. Szent Margit Kórház, Nefrológia Osztály, Budapest

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Beyond the blood sugar reduction. SGLT-2 inhibitors in kidney protection]

SIMONYI Gábor

[Results of cardiovascular safety studies with SGLT-2 inhibitors have shown that in addition to their hypoglycaemic and beneficial cardiovascular effects, they are renoprotective. A number of mechanisms underlying the renoprotective effects of SGLT-2 inhibitors have been shown to reduce albuminuria and deterioration of renal function. Their nephroprotective effects extend over a very wide range of eGFR and albuminuria categories. In the DAPA-CKD study, dapagliflozin was shown to exert its nephroprotective effect regardless of the presence of diabetes and a baseline eGFR, while also having a beneficial effect on cardiovascular endpoints and mortality. Following the confirmation of favourable renal results for SGLT-2 inhibitors, it is no coincidence that they have been included in national and international recommendations for the treatment of chronic kidney disease.]

Hypertension and nephrology

[SARS-CoV-2 fertőzés során kialakult alsó végtagi akut artériás elzáródás esete. „Örülök, hogy élek…”]

VIRÁG Éva, JACZÓ Zsuzsana, VÁRADI Tímea, RAPCSÁNYI Andrea, SZABÓ Ildikó, RADELECZKI Sándor, GASPARICS Roland, SIMONYI Gábor, BARANYAI Árpád, SKRIBEK Levente, NAGYSZEGI Dóra, FARKAS Katalin, KOLOSSVÁRY Endre

Hypertension and nephrology

[Telmisartan plus amlodipine single-pill combination therapy to achieve blood pressure goal values in hypertensive patients treated by general practitioners – an observational study]

ÁMON Tamás, BARACSI-BOTOS Viktória, MÉSZÁROS Ágota, JÁRAI Zoltán

[Background: Current European guidelines on the management of hypertension suggests a simple and easily applicable therapeutic strategy to increase effectiveness. Important component of this strategy is the application of single-pill combination (SPC) of RAS inhibitor in combination with calcium antagonists or diuretics as a first step. Primary objective: To assess the percentage of patients reached goal blood pressure ranges after 12 weeks of fix dose combination therapy with telmisartan plus amlodipine according to office blood pressure measurements in hypertensive patients treated by general practitioners (GPs). Patients and methods: After informed consent, 729 patients of 63 GP’s office participated in this multicentre, non-interventional, prospective data collection study. The intention-to-treat (ITT) population was 717, and primary endpoint was analysed in 690 patients (per protocol [PP] population). There were two visits during the study. Blood pressure was measured in all patients at the time of the enrollment and at the second and final visit. Results: The average age of the patients was 62±12 years, 55% of the patients were younger than 65 years, 357 patients (49.8%) of the population was male. The average office blood pressure at baseline was 150±17/88±10 mmHg, and decreased to 130±8.1/78±6.1 mmHg at 12 week (p<0.05). Pulse rate has decreased as well (from 80±9.8 /min to 75±6.3/min). At baseline 10.1% of the patients were at optimal systolic blood pressure goal, 15.8% at optimal diastolic blood pressure goal and only 5.5% simultaneously at systolic and diastolic goal. By the end of the observational period the percentage of patients reached optimal BP goal values increased to 51.6%, 54.1% and 33.0%, respectively (systolic, diastolic, systolic and diastolic). Also the proportion of those who achieved primary target BP below 140/90 mmHg was higher. At baseline 19.2% of patients had BP below 140/90 mmHg, which increased to 87.1% by the end of the study. Patients tolerated SPC telmisartan/amlodipine well, 95% of the patients continued to receive prescribed medication after study conclusion. Conclusion: These real world data shows that the introduction of a fix dose combination therapy after free combination therapy increases the success rate of treatment during a relative short period, however many of the patients would still need higher doses or additional therapy after 3 months in order to achieve the optimal BP target levels. ]

Hypertension and nephrology

[Dialysis service in coronavirus pandemic]

SZEGEDI János, HORN Péter, GERGELY László, TÖLGYESI Katalin, MOLNÁR Gergely

[The coronavirus pandemic started at December 2019 from Wuhan. The rate of spread of the coronavirus epidemic has shocked the entire world, and the WHO declared it as a pandemic in March 2020. The first case in Hungary was confirmed in March 2020. The infection primarily damages the lungs but can also infect other organs. The relationship between coronavirus infection and the kidney is bidirectional. On the one hand, the infection can cause acute renal damage, and on the other hand, chronic kidney patients and patients receiving renal replacement therapy are at increased risk of infection due to their immune compromised status. Chronic kidney patients are three times more likely to have a severe Covid-19 infection than the general population. Among patients with severe Covid-19, the incidence of acute renal failure may exceed. Patients treated with the HD program have a higher risk of infection due to transportation and treatment in the common area. The mortality rate of Covid-19 infected patients receiving renal replacement therapy is 20-35% according to international data. Infections occured in all the dialysis centers of the B.Braun Avitum Dialysis Network during both the 2nd and 3rd wave of the epidemic. Epidemiological data confirm that preventive measures are of paramount importance in the field of prevention of infections and in the care of the pandemic. Effective prevention and patient care can only be ensured on the basis of correct epidemiological data. The management of the B.Braun Avitum Dialysis Network decided at the time of the outbreak in Hungary to establish an Operational Staff to perform tasks related to the epidemic. The tasks of the Operational Staff are the following: to ensure an effective, up-to-date connection with the dialysis centers, to update the epidemiological data, and to develop and operate an effective prevention program and action plan. To address the epidemic situation, complex measures were introduced in the Network regulated in a pandemic plan which was periodically reviewed. This document includes detailed hygiene regulations regarding patient transport, screening of dialysis center entrants, proper use of mask and personal protective equipment, hand hygiene, contact and respiratory isolation, rules of behavior, ordering a visitation ban, and regulation of cooperation with the hospital. ]

Hypertension and nephrology

[Dialyzed patients with Covid-19 infection in Hungary in 2020]

KULCSÁR Imre

[We have observed the number and mortality of dialyzed patients with Covid-19 infection in 2020 in Hungary. We have summarized all of 54 dialysis facility where adult patients were treated. During the year, 1242 cases of infection were confirmed in patients undergoing dialysis. 16% (753/4704) of incident dialysis patients were infected. The number of dialysis patients with all Covid-19 infections was 1995. 31.1% of infected patients have died. The mortality was higher in large hemodialysis centers (patient transport, isolation difficulties, increased risk of contamination). Covid-19 positive patients treated with peritoneal dialysis (PD) had significantly lower mortality than those treated with hemodialysis (HD). Chronic kidney disease (CKD) is the most common risk factor for serious Covid-19 infections worldwide, which is why these patients require increased attention (especially for dialysis and transplant recipients). In 2020, there was no vaccine available in our country]

All articles in the issue

Related contents

Lege Artis Medicinae

[Insulin: alfa and omega]

KIS János Tibor, BALOGH Bernadett, KISS Zsófia, SCHANDL László

[Type 1 diabetes (T1DM) is caused by the autoimmune death of insulin-producing β-cells. In the background there is by all probability the primary antigen (if the theory of primary antigen is correct) the insulin itself or the proinsulin. However, treatment of T1DM is virtually equivalent to the insulin treatment. The earlier we recognize T1DM and start treatment, the better gly­caemic results we achieve, the more likely we can maintain all functional β-cell stocks. Insulin also plays a key role in the immunopathogenesis, development and treatment of T1DM, thus insulin is the alpha and omega in this condition.]

Hypertension and nephrology

[Extrapulmonary multiple organ damage and dysfunction in Covid-19]

KÉKES Ede, NAGY Judit

[SARS-CoV-2 virus attacks nőt only the lungs bút alsó many other or- gans (heart, kidney, liver, pancreas, gastrointestinal tract, brain, hematopoiesis) and regulatory system (RAAS, immuné system) to different degrees and with dif- ferent pathomechanisms. Accordingly, cell death, tissue damage and dysfunction or failure of somé organs has been developed. Our paper provides a detailed analysis of the incidence of extrapulmonary lesions, clinical manifestations, and the underlying pathomechanisms. This multi-organ damages was detected dom- inantly in severe Covid cases, bút may occur in moderate or mild cases. It should alsó be taken intő account that the consequences may occur after the acute phase, in a seronegative State - months after the onset of infection. In particu- lar, the heart (myocarditis, coronary insufficiency, arrhythmia), the kidney (acute renal failure and then permanent GFR decrease), glucose metabolism disorder (diabetes worsening, ketoacidosis, new diabetes) are the biggest therapeutic challenge. Multi-organ damage is due to direct virus-induced cell death, endo- thelial cell damage in the vascular system, and thrombo-inflammation with the formation of microthrombi, imbalance in the RAAS regulatory system, and early and delayed abnormal immuné response (cytokine storm).]

Hypertension and nephrology

[Beyond the diagnosis – the value of renal biopsy in clinical practice through the example of two glomerular diseases]

DOBI Deján

[In this review, the publications that established the value of renal biopsy in nephrology are referenced, the pathomechanism of lupus nephritis (LN) and IgA glomerulonephritis (IgAGN) is briefly summarized, and a detailed account is given on the previous and currently accepted classification systems of LN and IgAGN and on the prognostic relevance of these systems. ]

Lege Artis Medicinae

[POST-INFARCTION CARDIAC FAILURE]

TOMCSÁNYI János

[Recent advances in the care of acute myocardial infarction have resulted in more patients surviving myocardial infarction than earlier. However, heart failure is a common complication in these patients, which in turn is associated with substantial mortality, primarily due to a remodelling of the left ventricle that already starts in an early stage of the myocardial infarction. The aim of this review article is to present the pathomechanism of this remodelling and to discuss related therapeutic options. Current guidelines recommend the use of an angiotensin- converting enzyme inhibitor combined with or followed by an angiotensin receptor blocker, a beta-blocker, and an aldosterone antagonist in post-infarction patients with concomitant heart failure.]

Hypertension and nephrology

[Current diagnosis and treatment of membranous nephropathy]

STUDINGER Péter, CSEPREKÁL Orsolya, FINTHA Attila, KARDOS Magdolna, TISLÉR András

[Primary membranous nephropathy is a common glomerular disorder characterized by subepithelial immune deposits. The pathomechanism underlying these lesions has only recently been elucidated: M-type phospholipase A2receptor (PLA2R) protein emerged as being the leading autoantigen. Antibodies to PLA2R, typically of IgG4 subclass are expressed in 70-80% of patients with primary membranous nephropathy. The level of autoantibody to PLA2R was shown to correlate with disease severity and to change parallel with disease activity in response to therapy. While mild forms of the disease are prone to spontaneous remission and carry excellent prognosis, severe forms often progress into end-stage renal disease without treatment and necessitate immunosuppression. The latest guidelines recommend the application of corticosteroids with alkylating agents or calcineurin inhibitors as first-line therapy. Promising new therapies that are currently being explored for this disease include rituximab, mycophenolate mofetil, and adrenocorticotropic hormone.]